Related Experiment Video
Updated: Jul 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic
Fotios Barkas1, Moses Elisaf1, Haralampos Milionis1
1Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Insights
Familial hypercholesterolemia (FH) significantly increased stroke risk before statin therapy. The introduction of statins dramatically reduced this risk in individuals with heterozygous FH.
Area of Science:
- Cardiovascular Epidemiology
- Genetic Lipid Disorders
Background:
- Familial hypercholesterolemia (FH) is linked to premature heart disease.
- The association between FH and stroke risk remains debated.
Purpose of the Study:
- To conduct a meta-analysis on stroke incidence in heterozygous FH (HeFH) patients.
- To evaluate the impact of statin therapy on stroke risk in HeFH.
Main Methods:
- Systematic review and meta-analysis of four observational studies (3374 participants).
- Comparison of HeFH patients with the general population as controls.
- Analysis stratified by prestatin and statin eras (pre- and post-1987).
Main Results:
- Pre-statin era: HeFH significantly elevated stroke risk (OR = 7.658).
- Statin era: HeFH showed reduced odds for stroke (OR = 0.251).
Conclusions:
- HeFH is associated with increased cerebrovascular disease risk.
- Statin therapy significantly mitigates stroke risk in HeFH patients.
Background:
Familial hypercholesterolemia (FH) is undoubtedly associated with premature coronary heart disease, but it is debatable whether FH increases the risk for stroke.
Objective:
To meta-analyze available evidence regarding the incidence of stroke in individuals with heterozygous (He) FH.
Methods:
We conducted a systematic review and a meta-analysis of epidemiological studies, including English-language publications until June 2015; four observational studies, with 3374 participants with HeFH, were included in the analysis. Cerebrovascular disease comprised of ischemic stroke or transient ischemic attack. Since studies did not include any control subjects, the corresponding general population of the same reference area and period of time for each HeFH study served as control group. Analyses were performed according to the period of time during which the studies were conducted: prestatin and statin era (before and after 1987 when lovastatin was launched).
Results:
In the prestatin era, individuals with HeFH exhibited a higher risk for stroke compared with the general population [odds ratio (OR) = 7.658, 95% confidence interval (CI): 6.059-9.678, p < 0.01]. In contrast, FH subjects had a lower odds for stroke following the generalization of statin therapy (OR = 0.251, 95% CI: 0.176-0.358, p < 0.01).
Conclusions:
Taking into account the small number of studies and methodological issues, HeFH was associated with a higher risk of cerebrovascular disease compared with the general population in the prestatin era, which was significantly reduced after the introduction of statin therapy.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management

